November 29, 2016 - By kentuckypostne · 0 Comments
The stock of Carbylan Therapeutics Incorporated (NASDAQ:CBYL) registered an increase of 11.65% in short interest. CBYL’s total short interest was 269,300 shares in November as published by FINRA. Its up 11.65% from 241,200 shares, reported previously. With 233,900 shares average volume, it will take short sellers 1 days to cover their CBYL’s short positions. The short interest to Carbylan Therapeutics Incorporated’s float is 2.05%. The stock increased 1.09% or $0.11 during the last trading session, hitting $10.21. Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has declined 0.10% since April 26, 2016 and is downtrending. It has underperformed by 5.36% the S&P500.
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The company has a market cap of $23.16 million. The Firm is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. It currently has negative earnings. The Firm has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema (DME).
More notable recent Kalvista Pharmaceuticals Inc (NASDAQ:KALV) news were published by: Nasdaq.com which released: “KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics” on November 22, 2016, also Streetinsider.com with their article: “Form 3 KalVista Pharmaceuticals For: Nov 21 Filed by: Crockett Thomas Andrew” published on November 29, 2016, Quotes.Wsj.com published: “News KalVista Pharmaceuticals Inc.KALV” on October 05, 2016. More interesting news about Kalvista Pharmaceuticals Inc (NASDAQ:KALV) were released by: Globenewswire.com and their article: “Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share …” published on June 15, 2016 as well as Globenewswire.com‘s news article titled: “Carbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss …” with publication date: June 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.